INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE PROSECUTION OF THE SUBJECT APPLICATION

Applicants: T. Takagi et al. Attorney Docket No.: SNKYO126512

Application No.: 10/555,076 International Application No.: PCT/JP2004/06100

Mailed: October 28, 2005 International Filing Date: April 27, 2004

Title: ADIPONECTIN PRODUCTION ENHANCER

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
	U1	4,231,938	A	11/04/1980	Monaghan et al.
	U2	4,346,227	A	08/24/1982	Terahara et al.
	U3	4,444,784	A	04/24/1984	Hoffman et al.
	U4	4,739,073	A	04/19/1988	Kathawala
	U5	5,006,530	A	04/09/1991	Angerbauer et al.
	U6	5,260,440	A	11/09/1993	Hirai et al.
	U7	5,273,995	A	12/28/1993	Roth
	U8	5,854,259	A	12/29/1998	Fujikawa et al.
	U9	5,856,336	A	01/05/1999	Fujikawa et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	English Translation Provided
	F1	JP 9-71540	A	03/18/1997	JP		
	F2	WO 00/56403	A1	09/28/2000	WO		
	F3	WO 01/76573	A2	10/18/2001	WO		

OTHER INFORMATION
(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Cite No.	
	O1	Arita, Y., et al., "Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB-Binding Protein and Regulates Growth Factor-Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell," *Circulation 105*:2893-2898, June 18, 2002.

SNKYO\26512164.DOC

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

*Examiner Initial	Cite No.	
	O2	Arita, Y., et al., "Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity," *Biochemical and Biophysical Research Communications 257*(1):79-83, 1999.
	O3	Bellosta, S., et al., "Pleiotropic Effects of Statins in Atherosclerosis and Diabetes," *Diabetes Care 23*(Suppl. 2), April 2000, 1 p. (abstract), retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10860194&query_hl=2&itool=pubmed_DocSum> [retrieved October 5, 2005].
	O4	Berg, A.H., et al., "The Adipocyte-Secreted Protein Acrp30 Enhances Hepatic Insulin Action," *Nature Medicine 7*(8):947-953, August 2001.
	O5	Chaudhuri, A., "Vascular Reactivity in Diabetes Mellitus," *Current Diabetes Reports 2*:305-310, 2002.
	O6	Cingözbay, B.Y., et al., "Effects of Fluvastatin Treatment on Insulin Sensitivity in Patients With Hyperlipidaemia," *Journal of International Medical Research 30*:21-25, 2002.
	O7	Combs, T.P., et al., "Endogenous Glucose Production Is Inhibited by the Adipose-Derived Protein Acrp30," *Journal of Clinical Investigation 108*(12):1875-1881, December 2001.
	O8	Freeman, D.J., et al., "Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study," *Circulation 103*:357-362, January 23, 2001.
	O9	Hotta, K., et al., "Circulating Concentrations of the Adipocyte Protein Adiponectin Are Decreased in Parallel With Reduced Insulin Sensitivity During the Progression to Type 2 Diabetes in Rhesus Monkeys," *Diabetes 50*:1126-1133, May 2001.
	O10	Komai, T., "Effect of Statins on Glucose Metabolism," *Bio Clinica 17*(10):68-73, 2002.
	O11	Kondo, H., et al., "Association of Adiponectin Mutation With Type 2 Diabetes: A Candidate Gene for the Insulin Resistance Syndrome," *Diabetes 51*:2325-2328, July 2002.
	O12	Lindsay, R.S., et al., "Adiponectin and Development of Type 2 Diabetes in the Pima Indian Population," *Lancet 360*:57-58, July 6, 2002.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

*Examiner Initial	Cite No.	
	O13	MacMahon, S., et al., "Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis, Levels on the Progression of Carotid Atherosclerosis: Results of the LIPID Atherosclerosis Substudy," *Circulation 97*:1784-1790, May 12, 1998.
	O14	Maeda, K., et al., "cDNA Cloning and Expression of Novel Adipose Specific Collagen-Like Factor, apM1 (Adipose Most Abundant Gene Transcript 1)," *Biochemical and Biophysical Research Communications 221*(2):286-289, 1996.
	O15	Maeda, N., et al., "PPARγ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein," *Diabetes 50*:2094-2099, September 2001.
	O16	Mangaloglu, L., et al., "Treatment With Atorvastatin Ameliorates Hepatic Very-Low-Density Lipoprotein Overproduction in an Animal Model of Insulin Resistance, the Fructose-Fed Syrian Golden Hamster: Evidence That Reduced Hypertriglyceridemia Is Accompanied By Improved Hepatic Insulin Sensitivity, " *Metabolism 51*(4):409-418, April 2002.
	O17	McFarlane, S.I., et al., "Clinical Review 145: Pleiotropic Effects of Statins: Lipid Reduction and Beyond," *Journal of Clinical Endocrinology & Metabolism 87*(4):1451-1458, April 2002.
	O18	McVeigh, G.E., and J.N. Cohn, "Endothelial Dysfunction and the Metabolic Syndrome," *Current Diabetes Reports 3*:87-92, 2003.
	O19	Okamoto, Y., et al., "Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice," *Circulation 106*:2767-2770, November 26, 2002.
	O20	Ouchi, N., et al., "Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages," *Circulation 103*:1057-1063, February 27, 2001.
	O21	Ouchi, N., et al., "Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-κB Signaling Through a cAMP-Dependent Pathway," *Circulation 102*:1296-1301, September 12, 2000.
	O22	Ouchi, N., et al., "Novel Modulator for Endothelial Adhesion Molecules: Adipocyte-Derived Plasma Protein Adiponectin," *Circulation 100*:2473-2476, December 21/28, 1999.
	O23	Paolisso, G., et al., "Effects of Simvastatin and Atorvastatin Administration on Insulin Resistance and Respiratory Quotient in Aged Dyslipidemic Non-Insulin Dependent Diabetic Patients," *Atherosclerosis 150*:121-127, 2000.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

*Examiner Initial	Cite No.	
	O24	Reaven, G.M., "Role of Insulin Resistance in Human Disease," *Diabetes 37*:1595-1607, December 1988.
	O25	Ross, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s," *Nature 362*:801-809, April 29, 1993.
	O26	Shepherd, J., et al., "Pravastatin in Elderly Individuals at Risk of Vascular Disease (Prosper): a Randomised Controlled Trial," *Lancet 360*:1623-1630, November 23, 2003.
	O27	Sorisky, A., "Molecular Links Between Obesity and Cardiovascular Disease," *American Journal of Therapeutics 9*:516-521, 2002.
	O28	Weyer, C., et al., "Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association With Insulin Resistance and Hyperinsulinemia," *Journal of Clinical Endocrinology & Metabolism 86*(5):1930-1935, 2001.
	O29	Yamauchi, T., et al., "The Fat-Derived Hormone Adiponectin Reverses Insulin Resistance Associated With Both Lipoatrophy and Obesity," *Nature Medicine 7*(8):941-946, August 2001.
	O30	Yokota, T., et al., "Adiponectin, a New Member of the Family of Soluble Defense Collagens, Negatively Regulates the Growth of Myelomonocytic Progenitors and the Functions of Macrophages," *Blood 96*(5):1723-1732, September 1, 2000.
	O31	Zoccali, C., et al., "Adiponectin, Metabolic Risk Factors, and Cardiovascular Events Among Patients With End-Stage Renal Disease," *Journal of the American Society of Nephrology 13*:134-141, 2002.

Examiner **Date Considered**

7/5/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GER:mk/dmg

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100